These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22205272)

  • 41. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of biological agents in the treatment of rheumatoid arthritis.
    Fan PT; Leong KH
    Ann Acad Med Singap; 2007 Feb; 36(2):128-34. PubMed ID: 17364080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TNF inhibitors: a new age in rheumatoid arthritis treatment.
    Anderson DL
    Am J Nurs; 2004 Feb; 104(2):60-8; quiz 68-9. PubMed ID: 14767382
    [No Abstract]   [Full Text] [Related]  

  • 44. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [New ways in the management of rheumatoid arthritis in Hungary].
    Gergely P; Poór G
    Lege Artis Med; 2007 Oct; 17(10):657-64. PubMed ID: 19227595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.
    Mendonça JA; Marques-Neto JF; Samara AM; Appenzeller S
    Rheumatol Int; 2012 Mar; 32(3):815-8. PubMed ID: 21327431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
    Dejaco C; Duftner C; Wipfler E; Schirmer M
    Wien Med Wochenschr; 2009; 159(3-4):70-5. PubMed ID: 19247593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 52. [A patient with rheumatoid arthritis and primary biliary cirrhosis successfully treated with adalimumab].
    Bakula M; Mayer M; Čikeš N; Anić B
    Lijec Vjesn; 2015; 137(1-2):27-9. PubMed ID: 25906545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis.
    Berry CE; Tsai J; Tierney A; Pickles R
    Med J Aust; 2013 Apr; 198(6):331-3. PubMed ID: 23545033
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.
    Erten S
    Rheumatol Int; 2011 Nov; 31(11):1537-8. PubMed ID: 21120492
    [No Abstract]   [Full Text] [Related]  

  • 57. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effectiveness of rheumatoid arthritis therapies.
    Finckh A
    Curr Rheumatol Rep; 2010 Oct; 12(5):348-54. PubMed ID: 20652775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.